# Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors

> **NCT03950609** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 36 (actual)

## Conditions studied

- Advanced Carcinoid Tumor
- Digestive System Neuroendocrine Neoplasm
- Multiple Endocrine Neoplasia Type 1
- Neuroendocrine Neoplasm
- Unresectable Carcinoid Tumor

## Interventions

- **DRUG:** Everolimus
- **DRUG:** Lenvatinib

## Key facts

- **NCT ID:** NCT03950609
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-07-30
- **Primary completion:** 2028-03-30
- **Final completion:** 2028-03-30
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2026-03-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03950609

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03950609, "Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03950609. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*